Immutep Management
Management criteria checks 2/4
Immutep's CEO is Marc Voigt, appointed in Nov 2012, has a tenure of 11.5 years. total yearly compensation is A$1.11M, comprised of 39.5% salary and 60.5% bonuses, including company stock and options. directly owns 0.95% of the company’s shares, worth $3.24M. The average tenure of the management team and the board of directors is 6.4 years and 2 years respectively.
Key information
Marc Voigt
Chief executive officer
AU$1.1m
Total compensation
CEO salary percentage | 39.5% |
CEO tenure | 11.5yrs |
CEO ownership | 0.9% |
Management average tenure | 6.4yrs |
Board average tenure | 2yrs |
Recent management updates
Recent updates
Immutep: Realizing The Expected Catalysts, With More To Come
May 01Immutep stock climbs on FDA fast track status for eftilagimod to treat lung cancer subtype
Oct 04Immutep secures €1.8M cash in French government's research tax credit
Sep 23Immutep gets Japanese patent for immunotherapy eftilagimod alpha combo
Aug 30Immutep gets Japanese patent related to autoimmune disease drug candidate IMP761
Jul 06Immutep: Australian Immune-Focused Company, Pureplay LAG3 Player
Jun 12Immutep - LAG3 Checkpoint Receives First FDA Approval; Positive For This LAG3 Pure Play
Mar 21Immutep expands the evaluation of efti into a triple combination therapy, shares down 12%
Jun 21Immutep reveals anti-LAG-3 research program
Jun 08Immutep jumps 9% on Chinese patent for efti in chemo-immunotherapy combination
May 26Immutep completes recruitment in efti mid-stage study in head & neck cancer
Jan 07Immutep secures U.S. patent for Eftilagimod Alpha
Dec 29Immutep +72% after breast cancer trial shows promising survival data
Dec 09Immutep to enroll additional patients in mid-stage study with its lead cancer program
Nov 19Immutep rallies on Australian patent grant for IMP701 antibody
Nov 09CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | n/a | n/a | -AU$41m |
Sep 30 2023 | n/a | n/a | -AU$40m |
Jun 30 2023 | AU$1m | AU$440k | -AU$40m |
Mar 31 2023 | n/a | n/a | -AU$38m |
Dec 31 2022 | n/a | n/a | -AU$37m |
Sep 30 2022 | n/a | n/a | -AU$34m |
Jun 30 2022 | AU$943k | AU$428k | -AU$32m |
Mar 31 2022 | n/a | n/a | -AU$29m |
Dec 31 2021 | n/a | n/a | -AU$26m |
Sep 30 2021 | n/a | n/a | -AU$28m |
Jun 30 2021 | AU$995k | AU$409k | -AU$30m |
Mar 31 2021 | n/a | n/a | -AU$29m |
Dec 31 2020 | n/a | n/a | -AU$27m |
Sep 30 2020 | n/a | n/a | -AU$20m |
Jun 30 2020 | AU$926k | AU$411k | -AU$13m |
Mar 31 2020 | n/a | n/a | -AU$15m |
Dec 31 2019 | n/a | n/a | -AU$16m |
Sep 30 2019 | n/a | n/a | -AU$17m |
Jun 30 2019 | AU$837k | AU$399k | -AU$18m |
Mar 31 2019 | n/a | n/a | -AU$18m |
Dec 31 2018 | n/a | n/a | -AU$17m |
Sep 30 2018 | n/a | n/a | -AU$15m |
Jun 30 2018 | AU$1m | AU$401k | -AU$13m |
Mar 31 2018 | n/a | n/a | -AU$12m |
Dec 31 2017 | n/a | n/a | -AU$10m |
Sep 30 2017 | n/a | n/a | -AU$9m |
Jun 30 2017 | AU$668k | AU$329k | -AU$9m |
Compensation vs Market: Marc's total compensation ($USD736.66K) is below average for companies of similar size in the US market ($USD2.41M).
Compensation vs Earnings: Marc's compensation has increased whilst the company is unprofitable.
CEO
Marc Voigt (50 yo)
11.5yrs
Tenure
AU$1,114,122
Compensation
Mr. Marc Voigt has been the Chief Executive Officer of Immutep Limited (formerly, Prima BioMed Ltd) since July 9, 2014. Mr. Voigt has been an Executive Director of Immutep Limited since July 9, 2014. He se...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO, MD | 11.5yrs | AU$1.11m | 0.95% A$ 3.2m | |
COO, General Counsel & Joint Company Secretary | 11.6yrs | AU$595.80k | 0.27% A$ 939.7k | |
Chief Scientific Officer & Executive Director | 9.4yrs | AU$744.24k | 0.74% A$ 2.5m | |
Senior Vice President of Regulatory & Strategy | less than a year | no data | no data | |
Chief Medical Officer | less than a year | no data | no data | |
Joint Company Secretary | 3.3yrs | no data | no data |
6.4yrs
Average Tenure
50yo
Average Age
Experienced Management: IMMP's management team is seasoned and experienced (6.4 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO, MD | 9.8yrs | AU$1.11m | 0.95% A$ 3.2m | |
Chief Scientific Officer & Executive Director | 1.7yrs | AU$744.24k | 0.74% A$ 2.5m | |
Independent Non-Executive Chairman | 11yrs | AU$171.99k | 0.094% A$ 320.2k | |
Independent Non-Executive Deputy Chairman | 10.3yrs | AU$192.28k | 0.28% A$ 941.8k | |
Chairman of Clinical Advisory Board | 6.9yrs | no data | no data | |
Member of Clinical Advisory Board | 2yrs | no data | no data | |
Member of Clinical Advisory Board | 2yrs | no data | no data | |
Non-Executive Director | 1.1yrs | AU$62.32k | no data | |
Member of Clinical Advisory Board | 6.9yrs | no data | no data | |
Member of Clinical Advisory Board | 2yrs | no data | no data | |
Member of Clinical Advisory Board | 2yrs | no data | no data | |
Non-Executive Director | less than a year | no data | no data |
2.0yrs
Average Tenure
60.5yo
Average Age
Experienced Board: IMMP's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.